全球心绞痛治疗市场规模、份额、趋势和成长分析报告（2026-2034年）

预计到 2034 年，心绞痛治疗市场规模将从 2025 年的 29.7 亿美元成长至 43.7 亿美元，2026 年至 2034 年的复合年增长率为 4.41%。

由于全球心血管疾病发生率不断上升，全球心绞痛治疗市场正稳定扩张。心绞痛的特征是由于心臟供血不足引起的胸痛，在老龄化社会以及存在肥胖、吸烟和高血压等文明病因素的人群中仍然十分常见。需要长期心血管管理的患者数量不断增长，显着推动了对有效药物疗法的需求，这些疗法有助于缓解症状并提高患者的生活品质。

推动市场成长的因素包括药物研发的进步、新药製剂的开发以及人们对心臟病早期诊断和治疗意识提升。各国政府和医疗机构也正在实施心血管健康改善计划，这进一步刺激了对心绞痛药物的需求。此外，学名药的广泛普及使已开发国家和开发中国家的更多患者都能获得治疗选择，从而提高了药物的可近性和可负担性。

全球心绞痛治疗市场预计将保持强劲成长，这主要得益于持续研发带来的安全性和有效性不断提升的创新治疗方法的不断涌现。製药公司正大力投资药物研发和临床试验，以满足心血管疾病治疗领域尚未满足的需求。此外，个人化医疗的日益普及以及新兴市场医疗基础设施的改善，预计将为市场扩张创造新的机会。鑑于心血管疾病管理仍然是全球关注的重点，心绞痛治疗市场预计将持续成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球心绞痛治疗市场：依类型划分

• 市场分析、洞察与预测
• 稳定性心绞痛
• 不稳定型心绞痛
• 微血管性心绞痛
• 变异型心绞痛

第五章 全球心绞痛治疗市场：依药物类别划分

• 市场分析、洞察与预测
• β阻断剂
• 硝酸盐
• 抗血小板药物
• 钙离子通道阻断剂
• 抗凝血剂
• ACE抑制剂
• 其他药物类别

第六章：全球心绞痛治疗市场：依给药途径划分

• 市场分析、洞察与预测
• 口服
• 注射药物
• 局部的

第七章 全球心绞痛治疗市场：依通路划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房

第八章 全球心绞痛治疗市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • AdvaCare Pharma
  • Amgen
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim International
  • Eli Lilly And Company
  • Gilead Sciences
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Otsuka Pharmaceutical
  • Pfizer
  • Sanofi

The Angina Pectoris Drugs Market size is expected to reach USD 4.37 Billion in 2034 from USD 2.97 Billion (2025) growing at a CAGR of 4.41% during 2026-2034.

The Global Angina Pectoris Drugs Market is expanding steadily due to the increasing incidence of cardiovascular diseases across the world. Angina pectoris, characterized by chest pain caused by reduced blood flow to the heart, remains a common condition among aging populations and individuals with lifestyle-related risk factors such as obesity, smoking, and hypertension. The growing patient pool requiring long-term cardiovascular management is significantly boosting the demand for effective drug therapies that help alleviate symptoms and improve patient quality of life.

Several factors are driving market growth, including advancements in pharmaceutical research, the development of novel drug formulations, and increased awareness regarding early diagnosis and treatment of heart diseases. Governments and healthcare organizations are also implementing programs aimed at improving cardiovascular health, which further supports the demand for angina medications. In addition, the expanding availability of generic drugs has improved accessibility and affordability, making treatment options available to a broader patient base across both developed and developing regions.

Future prospects for the Global Angina Pectoris Drugs Market remain strong as ongoing research continues to introduce innovative therapies with improved safety and efficacy profiles. Pharmaceutical companies are investing heavily in drug development and clinical trials to address unmet medical needs in cardiovascular care. Furthermore, the growing adoption of personalized medicine and improved healthcare infrastructure in emerging economies are expected to create new opportunities for market expansion. As cardiovascular disease management remains a global priority, the angina pectoris drugs market is anticipated to witness sustained growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Stable Angina
• Unstable Angina
• Microvascular Angina
• Prinzmetal Angina

By Drug Class

• Beta Blockers
• Nitrates
• Anti-Platelets
• Calcium Channel Blockers
• Anticoagulants
• Ace Inhibitors
• Other Drug Classes

By Route Of Administration

• Oral
• Injectable
• Topical

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• AdvaCare Pharma, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim International, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Merck, Novartis, Otsuka Pharmaceutical, Pfizer, Sanofi
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANGINA PECTORIS DRUGS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Stable Angina Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Unstable Angina Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Microvascular Angina Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Prinzmetal Angina Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANGINA PECTORIS DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Class
• 5.2. Beta Blockers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Nitrates Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Anti-Platelets Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Calcium Channel Blockers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Anticoagulants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Ace Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Other Drug Classes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANGINA PECTORIS DRUGS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANGINA PECTORIS DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ANGINA PECTORIS DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Type
  • 8.2.2 By Drug Class
  • 8.2.3 By Route Of Administration
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Type
  • 8.3.2 By Drug Class
  • 8.3.3 By Route Of Administration
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Type
  • 8.4.2 By Drug Class
  • 8.4.3 By Route Of Administration
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Type
  • 8.5.2 By Drug Class
  • 8.5.3 By Route Of Administration
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Type
  • 8.6.2 By Drug Class
  • 8.6.3 By Route Of Administration
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ANGINA PECTORIS DRUGS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 AdvaCare Pharma
  • 10.2.2 Amgen
  • 10.2.3 AstraZeneca
  • 10.2.4 Bayer
  • 10.2.5 Boehringer Ingelheim International
  • 10.2.6 Eli Lilly And Company
  • 10.2.7 Gilead Sciences
  • 10.2.8 GlaxoSmithKline
  • 10.2.9 Merck
  • 10.2.10 Novartis
  • 10.2.11 Otsuka Pharmaceutical
  • 10.2.12 Pfizer
  • 10.2.13 Sanofi